Gallus Biopharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann Pick Type B Disease
Gallus Biopharmaceuticals has signed a development and manufacturing supply agreement with Genzyme.
Gallus Biopharmaceuticals, has signed a development and manufacturing supply agreement with Genzyme, a Sanofi company. As part of the multiyear agreement Gallus will provide process and method development, scale-up, clinical supply, and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B.
The firm based in St. Louis, Missouri, was established in 2010 and acquired a commercial biopharmaceutical manufacturing facility from Johnson & Johnson Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally.
Source: Gallus Biopharmaceuticals
Texas' MD Anderson Cancer Center Creates New Cell Therapy Institute
November 11th 2024With the launch of the Institute for Cell Therapy Discovery and Innovation, the MD Anderson Cancer Center will bring together expertise in developing cell therapies for cancer, autoimmune diseases, and infections.
